Renin-angiotensin system (RAS) inhibitors may delay progression of several chronic kidney diseases in adults. Two classes of RAS inhibitors - angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) - have been shown to have renoprotective abilities. Despite their different mechanisms of action, these two drug classes appear to have comparable antiproteinuric and renoprotective properties. Preliminary investigations suggest that combination therapy with an ACE inhibitor and ARB offers additional benefit. Only a few studies with these drugs for treatment of pediatric nephrology have been conducted; however, their results are encouraging. Additional clinical trials are needed to confirm these results.

New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.

ZAFFANELLO, Marco;
2008-01-01

Abstract

Renin-angiotensin system (RAS) inhibitors may delay progression of several chronic kidney diseases in adults. Two classes of RAS inhibitors - angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) - have been shown to have renoprotective abilities. Despite their different mechanisms of action, these two drug classes appear to have comparable antiproteinuric and renoprotective properties. Preliminary investigations suggest that combination therapy with an ACE inhibitor and ARB offers additional benefit. Only a few studies with these drugs for treatment of pediatric nephrology have been conducted; however, their results are encouraging. Additional clinical trials are needed to confirm these results.
2008
Angiotensin-Converting Enzyme Inhibitors; Angiotensin II Type 1 Receptor Blockers; children; nephropathy
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/314546
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact